Midazolam drug page Clinical trials

Trials with Midazolam

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

6Trials
2Recruiting
19Countries
1.866Planned patients

Showing 1–6 of 6

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Recruiting Phase 1 448 patients NCT06835569

The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

United States Mar 2025 – Aug 2029 Interventional
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Recruiting Phase 2 362 patients NCT04557449

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The…

United States, Argentina, China, Czechia and 4 more Sept 2020 – Nov 2027 Interventional
Combined with: PF-07220060
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Ongoing, not recruiting Phase 1 103 patients NCT05355701

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is…

United States, Canada, Israel Jul 2022 – Aug 2027 Interventional
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Ongoing, not recruiting Phase 1 30 patients NCT04973163

This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful…

United States, Belgium, Spain, United Kingdom Sept 2021 – Dec 2026 Interventional
Combined with: BI-1701963BI-1823911
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Finished Phase 1 713 patients NCT03600883

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutan…

United States, Australia, Austria, Belgium and 7 more Aug 2018 – May 2026 Interventional
Combined with: Sotorasib
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Finished Phase 1 210 patients NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

United States, Australia, France, Japan Sept 2016 – Oct 2022 Interventional

Where the recruiting trials are